life sciences news - Search News

Wave Life Sciences, Duchenne muscular dystrophy

Wave Life Sciences’ stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.

AOL · 14h

Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.

Seeking Alpha · 21h

Wave Life Sciences gains on data for Duchenne therapy

Wave Life Sciences (WVE) stock rises on positive interim data from a Phase 2 trial for for WVE-N531, a therapy for Duchenne muscular dystrophy (DMD). Read more here.

MarketWatch · 22h

Wave Life Sciences Shares Climb Premarket on Duchenne Study Data

Shares of Wave Life Sciences rose more than 10% in premarket trading Tuesday after the clinical-stage biotechnology company reported positive interim data from a mid-stage study of its WVE-N531 drug candidate in the neuromuscular genetic disease Duchenne muscular dystrophy.

23h

Formula 1 Precision Meets Life Sciences: How IoT Is Accelerating Innovation In Manufacturing

Just as F1 teams rely on real-time data to optimize performance, IoT is enabling life sciences manufacturers to achieve new ...

GlobeSt.com1d

Life Sciences Challenged By Overbuilding

Former Fed chairman Alan Greenspan coined the phrase "irrational exuberance" to describe the risk of unduly escalated asset ...

The Business Journals2d

Increased vacancy rates don't tell the full story when it comes to life sciences in Chicago

Here's why Chicago is expected to be a growth spot for life sciences in the coming years. Chicago is expected to be a ...

GlobalData on MSN22h

ReAlta Life Sciences doses first patient in trial of graft-versus-host disease drug

The primary goals of the study are to evaluate the safety and overall response rate in patients who are given RLS-0071.

Hartford Business17h

5 life sciences companies expanding in CT

Five life sciences companies are expanding their operations in Connecticut, including several that are leasing space in the ...

Business Eye on MSN1d

Irish Life Sciences Start-Up Secures €280,000 Enterprise Ireland Funding

Marama Labs, a life-sciences instrumentation start-up, has secured €280,000 in funding from Enterprise Ireland to fund the ...

21h

MJH Life Sciences® shares exclusive insights from the CEOs of America’s most dynamic emerging biotech organizations

By engaging with some of the most influential executives in the industry and the many organizations that advocate for them, the series will provide valuable perspectives on the evolving landscape of ...

22h

Axtria is Revolutionizing Field Force Management for Life Sciences and Pharma Companies

Life Sciences and Pharma industry leaders are turning to Axtria for cutting-edge solutions that boost field force ...

FiercePharma1d

Rejuveron Life Sciences rejuvenates as Centenara Labs

Swiss anti-aging biotech Rejuveron is seeking its rejuvenation as it morphs into Centenara Labs. | Swiss anti-aging biotech ...

Medicine Buffalo14h

UB CAT announces R&D collaboration awards to eight life sciences companies

Projects focus on cancer therapies, robotic clot removal catheters, and mRNA vaccines, among other technologies ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results